首页> 美国卫生研究院文献>The Journal of International Medical Research >Vasoplegia in patients with sepsis and septic shock: pathways and mechanisms
【2h】

Vasoplegia in patients with sepsis and septic shock: pathways and mechanisms

机译:败血症和败血性休克患者的血管痉挛:途径和机制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Sepsis is one of the most frequent causes of death among patients in intensive care units. Many therapeutic strategies have been assessed without the desired success rates. A key risk factor for death is hypotension due to vasodilatation with vascular hyposensitivity. However, the pathways underlying this process remain unclear. Endotoxemia induces inflammatory mediators, and this is followed by vasoplegia and decreased cardiac contractility. Although inhibition of these mediators diminishes mortality rates in animal models, this phenomenon has not been confirmed in humans. Downregulation of vasoconstrictive receptors such as angiotensin receptors, adrenergic and vasopressin receptors is seen in sepsis, which is associated with a hyporesponsiveness to vasoconstrictive mediators. Animal studies have verified that receptor downregulation is linked to the above-mentioned inflammatory mediators. Anti-inflammatory therapy with glucocorticoids reportedly improves responsiveness to catecholamines with higher survival in rats, although this has not been shown to be clinically significant in humans. Hence, there is an urgent need for in-depth studies investigating the underlying mechanisms of vasoplegia to allow for development of effective therapeutic strategies for the treatment of sepsis.
机译:脓毒症是重症监护病房患者中最常见的死亡原因之一。在没有期望的成功率的情况下,已经评估了许多治疗策略。死亡的关键危险因素是由于血管扩张引起的低血压以及血管敏感性低下。但是,此过程的基础途径尚不清楚。内毒素血症诱导炎症介质,然后是血管痉挛和心脏收缩力下降。尽管在动物模型中抑制这些介体可以降低死亡率,但尚未在人类中证实这种现象。在脓毒症中发现血管收缩受体如血管紧张素受体,肾上腺素能和血管加压素受体的下调,这与对血管收缩介体的低反应性有关。动物研究已证实受体下调与上述炎症介质有关。据报道,用糖皮质激素进行的抗炎治疗可改善对儿茶酚胺的反应性,并具有较高的存活率,尽管在人类中尚无临床意义。因此,迫切需要深入的研究以调查血管痉挛的潜在机制,以开发出用于治疗败血症的有效治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号